Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.71 |
| ▸ | MAP2K2 | P36507 | 16/20 | 0.58 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.58 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.58 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.58 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863864 | 0.90 | MAP2K1 (0.59) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL29781350 | 0.90 | MAP2K1 (0.76) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4819057 | 0.90 | MAP2K1 (0.69) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL4860946 | 0.87 | MAP2K1 (0.56) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4861481 | 0.87 | MAP2K1 (0.56) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4862668 | 0.84 | MAP2K1 (0.53) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4863007 | 0.84 | MAP2K1 (0.51) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4857107 | 0.83 | MAP2K1 (0.58) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| Zapnometinib SCHEMBL29362260 | 0.83 | MAP2K1 (1.00) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| Zapnometinib SCHEMBL1488782 | 0.83 | MAP2K1 (1.00) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7078438-B2 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-6960614-B2 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| CN-1219753-C | Oxygenated esters of 4-iodophenylamino phenoxy hydroxamic acid | WARNER LAMBERT CO (US) | 2005-09-21 | — | — | CN | disclosed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | disclosed |
| US-20050137263-A1 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY, LLC | 2005-06-23 | — | — | US | disclosed |
| EP-1467965-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | Warner-Lambert Company LLC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6770778-B2 | MAP KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; RESTENOSIS, PSORIASIS, AND ATHEROSCLEROSIS TREATMENT; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | PFIZER INC | 2004-08-03 | — | — | US | disclosed |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | REWCASTLE GORDON WILLIAM (NZ) | 2004-01-08 | — | — | US | disclosed |
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNET-LAMBERT COMPANY LLC | 2003-12-18 | — | — | US | disclosed |
| CN-1446197-A | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER LAMBERT CO (US) | 2003-10-01 | — | — | CN | disclosed |
| WO-2003062191-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062189-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | AADAC, EGLN3, HCAR2 | MAP2K1 4732/4885MAP2K2 4641/4885RAF1 4108/4885 |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885RAF1 4078/4885 |
| US-20040054172-A1 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | CYP4X1, ALOX5, HAAO | MAP2K1 4312/4885MAP2K2 4025/4885RAF1 4379/4885 |
| US-20050137263-A1 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | PAH, EGLN3, PAOX | MAP2K1 4555/4885MAP2K2 4495/4885RAF1 4003/4885 |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | HCAR2, EGLN3, AADAC | MAP2K1 4692/4885MAP2K2 4611/4885RAF1 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.